BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has been assigned a consensus rating of “Buy” from the eight ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $4.40.

Several equities analysts recently commented on the company. HC Wainwright set a $5.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a research note on Thursday, August 10th. Piper Jaffray Companies set a $4.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a research note on Wednesday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of BioDelivery Sciences International in a research note on Sunday, August 20th. FBR & Co set a $4.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a research note on Tuesday, May 16th. Finally, ValuEngine upgraded BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Friday, May 19th.

TRADEMARK VIOLATION WARNING: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/29/biodelivery-sciences-international-inc-bdsi-receives-4-40-average-price-target-from-brokerages.html.

A number of large investors have recently made changes to their positions in BDSI. Cutter & CO Brokerage Inc. raised its stake in shares of BioDelivery Sciences International by 2.4% in the second quarter. Cutter & CO Brokerage Inc. now owns 43,430 shares of the specialty pharmaceutical company’s stock valued at $122,000 after buying an additional 1,000 shares in the last quarter. Northern Trust Corp raised its stake in shares of BioDelivery Sciences International by 0.9% in the second quarter. Northern Trust Corp now owns 140,450 shares of the specialty pharmaceutical company’s stock valued at $394,000 after buying an additional 1,203 shares in the last quarter. NEXT Financial Group Inc raised its stake in shares of BioDelivery Sciences International by 9.3% in the second quarter. NEXT Financial Group Inc now owns 47,000 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 4,000 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in shares of BioDelivery Sciences International by 19.9% in the second quarter. Janney Montgomery Scott LLC now owns 71,800 shares of the specialty pharmaceutical company’s stock valued at $201,000 after buying an additional 11,900 shares in the last quarter. Finally, Advisor Group Inc. raised its stake in shares of BioDelivery Sciences International by 42.1% in the second quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock valued at $126,000 after buying an additional 13,341 shares in the last quarter. Institutional investors own 41.44% of the company’s stock.

Shares of BioDelivery Sciences International (NASDAQ BDSI) remained flat at $3.10 during midday trading on Friday. The company’s stock had a trading volume of 343,357 shares. The stock has a market cap of $171.97 million, a price-to-earnings ratio of 110.71 and a beta of 1.03. The stock has a 50-day moving average of $3.14 and a 200 day moving average of $2.35. BioDelivery Sciences International has a one year low of $1.50 and a one year high of $3.60.

BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.04. The business had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.45 million. BioDelivery Sciences International had a net margin of 3.34% and a return on equity of 14.64%. The business’s revenue for the quarter was up 74.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.31) earnings per share. On average, equities research analysts forecast that BioDelivery Sciences International will post $0.12 earnings per share for the current year.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Stock Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related stocks with our FREE daily email newsletter.